The Tau Pipeline Enabling Program (T-PEP)
The Alzheimer's Association and Tau Consortium have joined together to offer a unique opportunity to the global research community: The Tau Pipeline Enabling Program (T-PEP). This program seeks to accelerate the discovery of potential new therapies for tauopathies, including Alzheimer's (AD), Frontotemporal Dementia (FTD) and Progressive Supranuclear Palsy (PSP). The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of ideas into practical application.
Proposals responding to this program must target one or more steps in the drug discovery pipeline, including but not limited to i) assay development and high throughput screening, ii) lead optimization, and iii) IND-enabling studies, including related GMP scale-up/manufacture. Experimental drug compounds may be directed against the toxicity of tau directly and/or they may target their studies on potential neurobiological mechanisms that promote or synergize tau formation or toxicity, e.g. calcium dyshomeostatis, mitochondrial dysfunction, neuroinflammation, microtubule stability (or instability) and function, axon transport, synapse dysfunction/loss, and other tau-related mechanisms. Applications addressing related mechanisms must include the rationale that it will prevent, reduce, remove or otherwise mitigate the toxic effects of tau build up.
Both non-profit and small for-profit agencies are eligible. Preference will be given to for-profit companies with 50 or fewer employees. For-profits and non-profits must provide documentation verifying status. The Principal Investigator of the project must be a full- time faculty member or paid employee of the organization submitting the proposal. Applications from post-doctoral researchers will not be accepted. For questions about eligibility, please contact the Alzheimer's Association at firstname.lastname@example.org.
Full program details can be found at alz.org/T-PEP.
Letters of Intent (LOI) must be received by 5:00 PM ET, January 19, 2018.
CLOSED: Alzheimer’s Association Research Grant (AARG)
CLOSED: Alzheimer’s Association Research Grant to Promote Diversity (AARG-D)
CLOSED: Alzheimer’s Association Research Fellowship (AARF)
CLOSED: Alzheimer’s Association Research Fellowship to Promote Diversity (AARF-D)
CLOSED: Alzheimer’s Association Clinician Scientist Fellowship (AACSF)
CLOSED: Alzheimer’s Association Clinician Scientist Fellowship to Promote Diversity (AACSF-D)
For more information: Contact email@example.com or call 312.335.5747.
Next: Process and Timeline »